Tirzepatide: Difference between revisions
(Created page with "Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment") |
No edit summary |
||
| Line 1: | Line 1: | ||
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment | ||
[[Category:Pharmacology]] | |||
Revision as of 17:43, 18 August 2022
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment